Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1181–1190 of 1,190 studiesSort:

TerminatedInterventional · Phase 4NCT06578728 ↗
Intralesional Methotrexate Injections for the Treatment of Nail Psoriasis: an Intra-subject Randomized Controlled Trial
Shari LipnerPI
Intervention
Drug: Methotrexate · Drug: Triamcinolone Acetonide 10mg/mL · Drug: Saline
Dates
Sep 2025 – Jun 2026

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1181–1190 of 1,190 studiesSort:

TerminatedInterventional · Phase 4NCT06578728 ↗
Intralesional Methotrexate Injections for the Treatment of Nail Psoriasis: an Intra-subject Randomized Controlled Trial
Shari LipnerPI
Intervention
Drug: Methotrexate · Drug: Triamcinolone Acetonide 10mg/mL · Drug: Saline
Dates
Sep 2025 – Jun 2026

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Sponsor

Weill Medical College of Cornell University

Nail Psoriasis

CompletedInterventional · Phase 3NCT06584916 ↗

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Alpana P. ShuklaPI

Intervention: Drug: Orforglipron · Drug: Placebo
Dates: Sep 2024 – Nov 2025
Sponsor: Eli Lilly and Company

ObesityOverweight

TerminatedInterventional · Phase 2NCT06585150 ↗

A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Catherine Butkus SmallPI

Intervention: Drug: Obeldesivir · Drug: Obeldesivir Placebo
Dates: Oct 2024 – May 2025· Results posted
Sponsor: Gilead Sciences, Inc.

RSV Infection

TerminatedInterventional · Not applicableNCT06646939 ↗

Comparison of Community Reintegration Interventions Relative to the Institution of a Simulated Environment in Inpatient Rehabilitation and Pilot Study of the Impact of Simulated Environment on Functional Outcomes

Nasim ChowdhuryPI

Intervention: Behavioral: PT and OT with a simulated environment
Dates: Jul 2023 – Dec 2025
Sponsor: Weill Medical College of Cornell University

Simulated Environments for Community Reintegration

CompletedInterventional · Not applicableNCT06664788 ↗

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of ETHIZIA™ Versus SURGICEL® Original in Controlling Minimal, Mild, or Moderate Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic, Thoracic (Non-cardiac) and Extremity Surgery

Benjamin SamsteinPI

Intervention: Device: ETHIZIA · Device: SURGICEL Original
Dates: Apr 2025 – Sep 2026
Sponsor: Ethicon INC

HemostasisHemostatic Techniques

CompletedInterventional · Not applicableNCT06676072 ↗

Safety and Effectiveness of the TactiFlex SE Catheter and Volt Pulsed Field Ablation (PFA) Generator in Subjects With Paroxysmal Atrial Fibrillation

Steven M MarkowitzPI

Intervention: Device: PFA Ablation catheter
Dates: Nov 2024 – Apr 2026
Sponsor: Abbott Cardiovascular Systems, Inc.

Atrial Fibrillation (AF)Atrial ArrhythmiaParoxysmal AF+1 more

CompletedInterventional · Phase 3NCT06868264 ↗

Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection

Ilan Seth WeisbergPI

Intervention: Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR) · Drug: Sofosbuvir-Velpatasvir (SOF/VEL)
Dates: Apr 2025 – Jun 2026
Sponsor: Atea Pharmaceuticals, Inc.

HEPATITIS C VIRUS CHRONIC INFECTION

TerminatedInterventional · Phase 1/2NCT06983158 ↗

A Phase 1/2a, Open-Label, Multi-Center, Dose-Escalation Trial to Assess Safety, Tolerability, and Efficacy of a Single Dose of CAP-002 Gene Therapy Administered to Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

Zachary GrinspanPI

Intervention: Drug: gene therapy
Dates: Jul 2025 – Mar 2026
Sponsor: Capsida Biotherapeutics, Inc.

Developmental and Epileptic Encephalopathy

CompletedInterventional · Not applicableNCT06994325 ↗

A Pilot Hybrid Effectiveness-Implementation Trial for the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention

Parag GoyalPI

Intervention: Behavioral: Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention · Behavioral: Standard of Care (SOC)
Dates: Jul 2025 – Aug 2026
Sponsor: Weill Medical College of Cornell University

HFpEF - Heart Failure With Preserved Ejection Fraction

CompletedInterventional · Phase 2NCT07144293 ↗

Improving Physical Ability and Cellular Senescence Elimination in HIV

Carrie JohnstonPI

Intervention: Drug: Dasatinib · Drug: Quercetin · Other: Placebo - Dasatinib · Other: Placebo - Quercetin
Dates: Dec 2025 – Aug 2026
Sponsor: National Institute of Allergy & Infectious Diseases

HIVFrailtyPrefrail+1 more

‹ Prev 1 2 3 4 5…56 57 58 59 60Next ›